Radiation Colitis (Proctitis)

A colorectal-specific counterpart to Radiation Enteritis (small bowel): both arise from the same underlying radiation-vasculopathy mechanism, but this page covers the colon/rectum-specific presentation (classically hemorrhagic proctitis) and its distinct, largely endoscopic treatment armamentarium. Content below is from a textbook reference chapter (ASCRS Ch53 - Radiation, Microscopic, and Ischemic Colitis), not primary literature.

Definition and manifestation

Classified as acute (during therapy or within 6 months of completion) or chronic (persisting beyond 6 months, or new-onset after a latent period — most commonly 8–12 months post-treatment, but reported as late as 30 years out). Acute symptoms — diarrhea, mucous discharge, cramping, tenesmus, urgency, incontinence, pain — occur in 50–75% of patients undergoing pelvic radiation, from cell loss in the rapidly-turning-over rectal mucosa; they resolve as epithelial turnover restores the mucosa. Chronic radiation colitis does not resolve on its own — hemorrhagic proctitis (ranging from mild bleeding to life-threatening hemorrhage) is the most common chronic manifestation, from microvascular changes causing ischemia/fibrosis/bleeding. Chronic disease can also manifest with strictures and, rarely, perforation or fistula. Graded by the RTOG toxicity criteria (Table 53.1): Grade 1 (mild symptoms not requiring medication) through Grade 4 (obstruction, fistula, perforation, or transfusion-requiring bleeding).

Etiology and risk factors

An estimated 400,000 patients are diagnosed annually with cancers routinely treated with pelvic radiation (anal, cervical, prostate, rectal, less often bladder/endometrial), making previous pelvic radiation a routine finding in colorectal surgery practice. Incidence is dose-related: historically as high as 30%, now estimated at 1–5% with modern delivery techniques (IMRT, VMAT, CT-based planning). Doses <45 Gy rarely cause chronic colitis; doses >70 Gy cause significant injury. Standard long-course rectal cancer chemoradiation (45–54 Gy) carries lower colitis risk than cervical cancer treatment (45–50 Gy external beam followed by brachytherapy escalation to 90 Gy focally) — rectovaginal fistulas are most often seen after cervical cancer treatment and rectourethral fistulas after prostate treatment; both are unusual complications of standard rectal cancer treatment. Other risk factors: preexisting inflammatory bowel disease, and vascular-disease risk factors (diabetes, hypertension, nicotine use, peripheral vascular disease, adjuvant chemotherapy, previous surgery).

Prevention

Primary strategy is limiting radiation exposure to adjacent tissue: patient positioning, full-bladder techniques to displace bowel from the pelvis, CT-based planning, and advanced delivery techniques (IMRT, VMAT) using multiple beams with real-time organ-motion management. Pharmacologic prevention agents studied without demonstrated clear benefit: sucralfate enemas, short-chain fatty acids, probiotics. Glutamine enemas showed mixed results across two RCTs (one positive, one negative). Amifostine (an oxygen free-radical scavenger) is the most promising pharmacologic candidate but is not used in routine practice. Surgical prevention (mesh or omentum to exclude small bowel from the pelvis) has not been shown to reduce radiation colitis/enteritis incidence; preoperative laparotomy for this sole purpose is not recommended.

Diagnosis

No specific laboratory studies are diagnostic; severe hemorrhagic colitis may show significant anemia, and stricture-related obstruction may show metabolic disturbances. Imaging is nonspecific. Clinical history and endoscopic appearance are the mainstays of diagnosis — classic findings are pallor with telangiectasias and easy friability. Biopsy is only needed if the diagnosis is in question; when the diagnosis is clear, biopsy should be avoided as it has been shown to increase fistula risk. Histology in the acute phase shows inflammatory changes (eosinophilic submucosal infiltration, crypt atrophy, crypt abscesses); the chronic phase shows small-vessel vasculopathy, obliterative endarteritis with ulceration and fibrous induration, and vascular intimal fibrosis without inflammation.

Management

Medical

Focuses on controlling pain, mucous discharge, tenesmus, and rectal hemorrhage. Sucralfate enemas have the best supporting data among medical options — twice-daily 20mL enemas produced improvement in 77% of patients at 1 month and 92% at 4 months in one series — but the practical burden of long-term self-administered enemas limits its use for moderate symptom improvement. Metronidazole has shown symptom reduction in two studies without an established ideal regimen. Antioxidant vitamins (A, E, C) show benefit in small studies without sufficient data for a standard recommendation; mesalamine/other ASA derivatives and steroids lack sufficient supporting data. Hyperbaric oxygen therapy is effective (one series: 89% success in 39 patients) but requires 36–40 treatment sessions at considerable time/cost, which has made endoscopic therapy the more practical first-line option.

Endoscopic (first-line for hemorrhagic radiation proctitis)

• Topical formalin — the authors' preferred therapy given ease of use, ready availability, excellent success rates, and low complication rate. Administration varies (spray via flexible sigmoidoscope, retention enema, or a formalin-soaked cotton applicator/gauze held against the mucosa), typically 1–3 sessions. Reported success rates 62–100% across multiple series (one of the largest, 100 patients, reported 93% success). Complications are uncommon when technique is careful; perianal skin should be protected (e.g. lidocaine jelly) given formalin's causticity, and one outlier series reported a 20% severe-complication rate as a cautionary note against careless technique.
• Argon beam coagulation (ABC) — similar effectiveness to formalin (reported success rates 81–86%), with more uniform/predictable penetration depth (1–3mm) than formalin, and found nearly equivalent to formalin in a direct comparison. A 20% rectal ulcer rate has been reported, but these are typically asymptomatic and self-resolving. Main practical limitation is training/equipment availability rather than efficacy.
• Other modalities (bipolar electrocoagulation, Nd:YAG laser, radiofrequency ablation, cryotherapy) have much less supporting data and require specialized equipment; Nd:YAG's deeper, more variable penetration (~5mm) carries a higher perforation risk than formalin/ABC.
• Endoscopic balloon dilation is an option for radiation-related strictures despite these strictures tending to be firm and poorly compliant; distal strictures accessible transanally can be dilated more aggressively with Hegar dilators.

Surgical (last resort)

Reserved for refractory bleeding, obstructing strictures, fistulas, or disabling symptoms. Resection (with or without reconstruction) or diversion alone are the two broad options. Resectional procedures are technically difficult given radiation-induced alteration of anatomical planes, loss of tissue compliance, and severe adhesions — historical series report very high morbidity/mortality (one 1985 French series: 33% mortality, 30% enterocutaneous fistula rate after laparotomy for radiation injury, likely reflecting selection bias toward the most complicated patients; a Mayo Clinic series found 80% complication and 14% mortality rates). Rectovaginal fistula resection is particularly limited by high cervical-cancer radiation doses — one series found resection possible in only 4% of patients, with most requiring diversion alone; even when resection succeeds, ostomy closure is often not ultimately achievable. Diversion improves quality of life and incontinence/obstruction-related symptoms, but does not reliably resolve bleeding, pain, mucous drainage, or tenesmus. In patients with reasonable health status, resection should be considered when tissue is amenable, as it offers the chance to remove all active disease — but patients and surgeons must be prepared that reconstruction is often not technically feasible or medically appropriate, and a permanent ostomy is frequently required.

Open items / gaps

• All content above is textbook-level/secondary. Six load-bearing named studies across this chapter's three conditions (not specific to radiation colitis itself) are flagged in Research Priorities.md for independent ingestion.
• No primary literature yet independently appraising the individual formalin/ABC administration series cited above (Sharma, Haas, Raman, Sebastian, Zinicola, Yeoh) — currently only the textbook's narrative summary of each.
• See Radiation Enteritis for the small-bowel counterpart of radiation injury — same underlying vasculopathy mechanism, distinct anatomic presentation and management.